Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Anticonvulsants Stories

2014-01-09 11:48:50

A new study finds that the epilepsy drug levetiracetam appears not to be associated with thinking, movement and language problems for preschool children born to mothers who took the drug during pregnancy, although the drug valproate was associated with some difficulties in preschoolers. The study is published in the January 8, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. "These results are heartening, as the use of levetiracetam has increased...

2014-01-07 23:00:19

http://www.DrugNews.net is the web’s premier source for prescription device warnings, research, side effects and legal news. Visit the DrugNews Center today. New York, NY (PRWEB) January 07, 2014 The prescription drug safety advocates at DrugNews.net have launched a 2014 Topamax Center for parents who took the antiepileptic drug while pregnant. The site has compiled research on the drug’s side effects, as well as safety alerts for patients, and legal news for claims alleging birth...

2014-01-06 10:16:35

Gabapentin is a gamma-aminobutyric acid derivative, and was approved for the treatment of neuropathic pain by the U.S. Food and Drug Administration in 2002. However, little evidence is available on the effects and me-chanisms of action of gabapentin during the migraine attack period. A recent study by Yanbo Zhang and colleague from Xuanwu Hospital, Capital Medical University in China showed that excitatory amino acids and protein kinase C are involved in the formation and maintenance of...

2014-01-02 08:23:03

FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist WOODCLIFF LAKE, N.J., Jan. 2, 2014 /PRNewswire/ -- Eisai Inc. announced today that FYCOMPA(TM) (perampanel) CIII will be available to eligible patients by prescription in the U.S. beginning January 6, 2014. FYCOMPA is an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy age 12 years and older. FYCOMPA is...

2013-12-19 23:32:23

A national law firm providing pharmaceutical litigation services, Carey Danis & Lowe shares their expert legal opinion on the future of Topamax cases. St. Louis, Missouri (PRWEB) December 19, 2013 The personal injury litigation firm, Carey Danis & Lowe, represents those who have been harmed by defective drugs, and imparts their thoughts on the future of certain defective drug cases in light of the recent verdict in a Philadelphia court hearing a Topamax case known as Gurley v....

2013-12-16 12:24:46

Older, Generic Mainstays Will Remain at the Core of Epilepsy Treatment, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market for epilepsy pharmacotherapies will expand at a rate of 2 percent annually through 2022, peaking at more than $4.1 billion in 2020. Market growth will be fueled primarily by...

2013-12-10 08:31:19

Impact of Delayed-Dose Administration Results also Announced at the American Epilepsy Society Annual Meeting MAPLE GROVE, Minn., Dec. 10, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced the presentation of new Phase 1 data showing that USL255 (extended-release topiramate) may provide a beneficial treatment option for individuals with difficulty swallowing whole capsules or tablets. Additionally, simulations of data from another Phase 1 study...

2013-12-09 08:30:31

Efficacy and Safety/Tolerability Findings Presented at 2013 American Epilepsy Society Annual Meeting MAPLE GROVE, Minn., Dec. 9, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) today presented results from its global Phase 3 (PREVAIL) study of USL255 (extended-release topiramate), showing that the investigational drug met its primary and secondary endpoints for efficacy and demonstrated favorable safety and tolerability in epilepsy patients with refractory partial-onset...

2013-12-06 23:23:34

The DrugRisk Resource Center is the Web’s largest source for information on prescription drug research, side effects and legal news. Visit http://www.DrugRisk.com Atlanta, GA (PRWEB) December 06, 2013 The DrugRisk.com prescription drug safety center is announcing it has added information for women who have taken the anticonvulsant drug Topamax. The new resource center contains studies on birth defect side effects, safety alerts for patients, as well as legal news for any birth defect...

2013-12-06 23:22:11

According to Bloomberg (11/19/13), a Philadelphia jury ordered J&J's Janssen to pay $11 million in a case claiming that Topamax caused birth defects. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Topamax side effects. San Diego, CA (PRWEB) December 06, 2013 AttorneyOne.com, a recognized authority on law, updated the website...